Citi raised the firm’s price target on Intuitive Surgical (ISRG) to $640 from $567 and keeps a Buy rating on the shares as part of a 2025 outlook for the U.S. medical technology sector. The stocks that outperformed in 2024 followed the traditional med tech path, and Citi expects the same in 2025: launching differentiated products that can be leveraged to the bottom-line, with management teams providing consistent delivery, the analyst tells investors in a research note. Citi names Boston Scientific (BSX) and Insulet (PODD) its top picks for 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ISRG:
- Intuitive announces publication of 30-day surgical outcomes involving da Vinci
- Intuitive Surgical price target raised to $610 from $525 at Stifel
- Intuitive Surgical assumed at Overweight from Equal Weight at Morgan Stanley
- Intuitive Surgical price target raised to $561 from $535 at BTIG
- Trump Trade: President-elect seeks to kill Biden fuel-efficiency rules